Innovations November 2018
Total Page：16
File Type：pdf, Size：1020Kb
INNOVATIONS NOVEMBER 2018 Sex and the HIV Reservoir The power of estrogen Also Inside: Preparing for Potential Game Changers When Size Matters: Social Media and Key Populations A “Dangerous Complacency” Threatens Global HIV Response amfAR, The Foundation for AIDS Research amfar.org COVER STORY 8–9 NOVEMBER 2018 Sex and the HIV Reservoir The biannual newsletter of amfAR, A study led by amfAR-funded scientist Dr. Jonathan Karn suggests The Foundation for AIDS Research that women may respond differently than men to some potentially 120 Wall Street, 13th Floor curative interventions that are currently under investigation. New York, NY 10005-3908 T: (212) 806-1600 F: (212) 806-1601 POLICY 1100 Vermont Ave. NW Suite 600 Washington, DC 20005 4 Preparing for Potential Game Changers T: (202) 331-8600 5 AIDS Conference Shines Spotlight on Global Epidemic F: (202) 331-8606 6 Impact of Mexico City Policy on PEPFAR TREAT Asia Exchange Tower 7 When Size Matters: How Social Media Can Help Determine 388 Sukhumvit Road Key Population Size Suite 2104 Klongtoey, Bangkok 10110 RESEARCH Thailand T: (+66) 2 663-7561 9 Second Annual São Paulo HIV Cure Research Summit F: (+66) 2 663-7562 10 amfAR Renews Investment in European HIV Cure www.amfar.org Consortium Innovations Staff: 10 The Mathilde Krim Effect Andrew McInnes, Editor Adam Winters, Senior Staff Writer 11 Research Highlights from AIDS 2018 Claudia Kaplan, Senior Staff Writer 11 The CHAMP Study: Clues to Natural Control of HIV Raoul Norman-Tenazas, Creative Director GLOBAL Yolande Hunter-Johnson, Creative Coordinator 12 Funding Gaps Could Put Asia Further Behind on HIV/AIDS 13 A “Dangerous Complacency” Is Threatening the Global HIV Response 14 Resources to Support Transition of Adolescents from Pediatric to Adult HIV Care 14 Hepatitis C: Policy Recommendations for Addressing a Growing Epidemic amfAR meets the BBB Wise Giving Alliance’s FEATURE Standards for Charity Accountability 15 Donor Profile: Faith Peterson EVENTS 16 Benefit Event Highlights (amfAR Gala Cannes, Hong Kong, Paris, and São Paulo; Epic Ride to Life Ball; and more) From the CEO Photo: Getty Images The Power to Transform and Overcome I wish you could join us when our scientific reviewers gather cells), and molecular scissors targeting the virus. It’s an at amfAR’s offices to discuss research grant applications and ambitious project—with breakthrough potential. decide which ones are most worthy of funding. The science is complex, to be sure, but the animated interactions of the We have also just announced a new round of Mathilde Krim reviewers, their scientific expertise, and their unswerving Fellowships in Basic Biomedical Research. Launched a commitment to achieving a cure for HIV are an inspiration. decade ago, this program has proven highly successful in With their help, we’re able to fund the best projects that align nurturing bright young researchers and bringing new talent with our cure research strategy. and fresh ideas to the field of HIV research. At press time, amfAR’s Board of Trustees had just approved The Krim Fellowships are profiled in a special issue of the a new round of grants, which we’ll report on in full in the next journal AIDS Research and Human Retroviruses honoring Dr. issue of Innovations (and on our website at www.amfar.org). Krim, our Founding Chairman, who passed away in January While all hold promise for advancing our search for a cure, (see page 10). The journal showcases the work of recent Krim we’re particularly excited about a gene therapy project we’re Fellows and leads with tributes from amfAR leadership and calling ARCHE-GT. The aim is to completely eradicate HIV former Krim Fellow Dr. Nuria Izquierdo-Useros. She writes, from the body. “I truly believe that research has the power to transform society and overcome some of the biggest challenges amfAR has forged a unique collaboration among world humankind faces. Basic research holds the potential to end leaders in gene therapy to create the first combination HIV and to finally find a cure for millions of people who are intervention that will simultaneously address the main infected around the world.” barriers to a cure. In a three-pronged attack on the HIV reservoir, ARCHE-GT will employ broadly neutralizing We wholeheartedly agree. antibodies, specially designed CAR stem cells (cells genetically reprogrammed to recognize and attack disease www.amfar.org Policy Preparing for Potential Game Changers What needs to happen before long-acting antiretrovirals come to market? the range of potential delivery mechanisms (e.g., pills, injectables, implants, intravaginal rings) and work to expeditiously review new drug applications and provide clear guidance for manufacturers and the public on key issues. Defining the Intended Market for New Products: Innovative products that may be more expensive than existing therapies raise complex questions over how to define their role in relation to current treatment and prevention options. Related questions about the uptake of long-acting therapies and their impact on adherence also must be considered, as well as factors that will influence consumer demand and provider willingness to prescribe them. Policy makers should plan to proactively monitor and invest in necessary studies to document impact and While treatment for HIV infection has become advance the process, amfAR has produced a identify unresolved issues. more effective and less complicated in recent series of reports that describe the critical issues Payer Coverage and Access Decisions: years, it still involves taking a pill or pills each that must be navigated to make these potentially Medicaid, Medicare, the Ryan White HIV/AIDS day for life. But innovative new products could game-changing new products available for Program, and private health insurance programs revolutionize HIV treatment and prevention. people living with HIV or vulnerable to infection. operate under different laws and rules regarding Sometimes called long-acting agents, these pharmaceutical coverage. Federal agencies products may take different forms, ranging from Policy makers must assess and navigate a should begin to consider, in advance, how injections to implants to oral medications, and variety of issues: they will evaluate new long-acting products they would not require daily dosing. Some might FDA Review and Approval: The Food and Drug and how they can provide early guidance for require a monthly dose, while others could be Administration (FDA) must determine that new purchasers, prescribers, and the public on how administered a few times a year. Long-Actingproducts HIV are Treatment safe and effective. and Prevention They also is willComing new products will be evaluated and integrated Long-Acting HIV Treatment and Prevention is Coming Taking an idea and turning it into a desirable, Preparingneed to consider for Potential unique questions Game Changersrelated to into drug formularies. Preparing for Potential Game Changers effective, affordable, and accessible product long-acting products such as the potential to The full reports are available at is a long and difficult process. To facilitate spur drug resistance. Policy makers should bring www.amfar.org/Long-Acting-ARV/ the analysis and policy decisions needed to together relevant parts of the FDA to consider FIGURE 1. WHAT IS ON THE HORIZON? effective, coverage decisions by payers turn on whether a product Establishing the standards by which CURRENT IN DEVELOPMENT is “reasonable and necessary.”. While what is reasonable is highly payers determine whether a therapy is Injectables Implants Oral subjective, medical necessity determinations often have multiple HIV Treatment 40 single-agent antiretroviral At least 10 products At least 2 products At least 1 product is in components, including whether a therapy is needed for a specific medically necessary for an individual and combination antiretroviral are in development are in development that development that could condition (e.g., to treat HIV infection or to prevent HIV acquisition), patient will be critically important. products approved for use in that could be injected. could be implanted under be taken orally. Dosing and whether better or equivalent, yet cheaper products are already the U.S., including 1 injectable Dosing frequency could the skin or in the body. frequency could be available. There are related costs that must be covered in addition important, as well as determining which policy and financial tools to product be approximately every Dosing frequency could around once a week. to the medication, such as laboratory tests and monitoring by a use to manage access. 8 weeks. be as little as once a health care provider. If a product involves something that requires year. HIV Prevention 1 combination antiretroviral physician administration, however, how these related services and The Centers for Medicare and Medicaid Services (CMS), the Health product approved for use in how the therapy itself is paid for may change. In Medicare, for Resources and Services Administration (HRSA), and relevant other the U.S. example, the Part B program covers physician-administered drugs agencies, as well as the Department of Health and Human Services and the Part D program covers most outpatient prescription drugs; (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents 4 Innovations, November 2018 each has its own coverage requirements. Therefore, different long- and the U.S. Public Health Service (PHS), should begin to review Policy makers should begin planning